{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:43:08Z","timestamp":1792640588782,"version":"4.5.0"},"reference-count":92,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T00:00:00Z","timestamp":1685318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Hidradenitis suppurativa (HS) is a chronic, recurrent, and inflammatory skin disease characterized by painful, deep-seated, nodules, abscesses, and sinus tracts in sensitive areas of the body, including axillary, inguinal, and anogenital regions. Antibiotics represent the first-line pharmacological treatment of HS because of their anti-inflammatory properties and antimicrobial effects. This narrative review summarizes the most significant current issues on the role of systemic antibiotics in the management of HS, critically analyzing the main limits of their use (antibiotic resistance and toxicity). Although, in the last decades, several cytokines have been implicated in the pathomechanism of HS and the research on the use of novel biologic agents in HS has been intensified, antibiotics remain a valid therapeutic approach. Future challenges regarding antibiotic therapy in HS comprise their use in association with biologics in the management of acute flare or as a bridge therapy to surgery.<\/jats:p>","DOI":"10.3390\/antibiotics12060978","type":"journal-article","created":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T07:54:16Z","timestamp":1685346856000},"page":"978","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Systemic Antibiotic Therapy in Hidradenitis Suppurativa: A Review on Treatment Landscape and Current Issues"],"prefix":"10.3390","volume":"12","author":[{"given":"Elisa","family":"Molinelli","sequence":"first","affiliation":[{"name":"Dermatological Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"De Simoni","sequence":"additional","affiliation":[{"name":"Dermatological Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Candelora","sequence":"additional","affiliation":[{"name":"Dermatological Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Sapigni","sequence":"additional","affiliation":[{"name":"Dermatological Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Brisigotti","sequence":"additional","affiliation":[{"name":"Dermatological Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0091-4067","authenticated-orcid":false,"given":"Giulio","family":"Rizzetto","sequence":"additional","affiliation":[{"name":"Dermatological Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Offidani","sequence":"additional","affiliation":[{"name":"Dermatological Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriana","family":"Simonetti","sequence":"additional","affiliation":[{"name":"Dermatological Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1111\/ced.13861","article-title":"Sex-related Differences of Clinical Features in Hidradenitis Suppurativa: Analysis of an Italian-based Cohort","volume":"44","author":"Bianchi","year":"2019","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/jid.2012.255","article-title":"Incidence of Hidradenitis Suppurativa and Associated Factors: A Population-Based Study of Olmsted County, Minnesota","volume":"133","author":"Vazquez","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/ijd.14036","article-title":"Ertapenem\u2014A Potent Treatment for Clinical and Quality of Life Improvement in Patients with Hidradenitis Suppurativa","volume":"57","author":"Braunberger","year":"2018","journal-title":"Int. J. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1080\/17512433.2020.1762571","article-title":"The Pharmacology of Antibiotic Therapy in Hidradenitis Suppurativa","volume":"13","author":"Marasca","year":"2020","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1111\/bjd.14038","article-title":"Diagnostic Delay in Hidradenitis Suppurativa Is a Global Problem","volume":"173","author":"Saunte","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Molinelli, E., Sapigni, C., D\u2019Agostino, G.M., Brisigotti, V., Rizzetto, G., Bobyr, I., Cirioni, O., Giacometti, A., Brescini, L., and Mazzanti, S. (2022). The Effect of Dalbavancin in Moderate to Severe Hidradenitis Suppurativa. Antibiotics, 11.","DOI":"10.3390\/antibiotics11111573"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/bjd.15448","article-title":"Health-Related Quality of Life in Hidradenitis Suppurativa","volume":"176","author":"Ofenloch","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1111\/jdv.15235","article-title":"Comparison of Clinical and Ultrasound Scores in Patients with Hidradenitis Suppurativa: Results from an Italian Ultrasound Working Group","volume":"33","author":"Napolitano","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/jdv.15847","article-title":"Ultrasonography in the Pathway to an Optimal Standard of Care of Hidradenitis Suppurativa: The Italian Ultrasound Working Group Experience","volume":"33","author":"Lacarrubba","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000503605","article-title":"A Comparison of International Management Guidelines for Hidradenitis Suppurativa","volume":"237","author":"Hendricks","year":"2021","journal-title":"Dermatology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/bjd.15748","article-title":"Development and Validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a Novel Dynamic Scoring System to Assess HS Severity","volume":"177","author":"Zouboulis","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1111\/jdv.16642","article-title":"Validity of EQ-5D-5L, Skindex-16, DLQI and DLQI-R in Patients with Hidradenitis Suppurativa","volume":"34","author":"Gergely","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"515","DOI":"10.5021\/ad.2021.33.6.515","article-title":"Clindamycin Mono-Therapy of Hidradenitis Suppurativa Patients: A Single-Center Retrospective Study","volume":"33","author":"An","year":"2021","journal-title":"Ann. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.23736\/S0392-0488.17.05798-4","article-title":"Update on Pathogenesis of Hidradenitis Suppurativa","volume":"153","author":"Napolitano","year":"2018","journal-title":"Ital. J. Dermatol. Venereol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Biernat, M.M., and Wr\u00f3bel, T. (2021). Bacterial Infection and Non-Hodgkin B-Cell Lymphoma: Interactions between Pathogen, Host and the Tumor Environment. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147372"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1080\/10428190701618250","article-title":"Clinicopathological Features of Primary Cutaneous B-Cell Lymphomas from an Academic Regional Hospital in Central Italy: No Evidence of Borrelia burgdorferi Association","volume":"48","author":"Goteri","year":"2007","journal-title":"Leuk. Lymphoma"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/exd.12793","article-title":"The Bacteriology of Hidradenitis Suppurativa: A Systematic Review","volume":"24","author":"Ring","year":"2015","journal-title":"Exp. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.det.2015.08.010","article-title":"The Microbiology of Hidradenitis Suppurativa","volume":"34","author":"Ring","year":"2016","journal-title":"Dermatol. Clin."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jaad.2019.02.067","article-title":"North American Clinical Management Guidelines for Hidradenitis Suppurativa: A Publication from the United States and Canadian Hidradenitis Suppurativa Foundations","volume":"81","author":"Alikhan","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/ced.14388","article-title":"Lymecycline vs. Clindamycin plus Rifampicin in Hidradenitis Suppurativa Treatment: Clinical and Ultrasonography Evaluation","volume":"46","author":"Molinelli","year":"2021","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0065-2164(04)56004-5","article-title":"Lincosamides: Chemical Structure, Biosynthesis, Mechanism of Action, Resistance, and Applications","volume":"56","year":"2004","journal-title":"Adv. Appl. Microbiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/jac\/7.suppl_A.3","article-title":"Antibacterial Activity and Pharmacokinetics of Clindamycin","volume":"7","author":"Leigh","year":"1981","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-4362.1983.tb02150.x","article-title":"Topical Treatment of Hidradenitis Suppurativa with Clindamycin","volume":"22","author":"Clemmensen","year":"1983","journal-title":"Int. J. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0190-9622(98)70272-5","article-title":"Topical Clindamycin versus Systemic Tetracycline in the Treatment of Hidradenitis Suppurativa","volume":"39","author":"Jemec","year":"1998","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/bjd.19337","article-title":"Efficacy and Safety of Topical Resorcinol 15% as Long-term Treatment of Mild-to-moderate Hidradenitis Suppurativa: A Valid Alternative to Clindamycin in the Panorama of Antibiotic Resistance","volume":"183","author":"Molinelli","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e15439","DOI":"10.1111\/dth.15439","article-title":"Efficacy and Safety of Topical Resorcinol 15% versus Topical Clindamycin 1% in the Management of Mild-to-moderate Hidradenitis Suppurativa: A Retrospective Study","volume":"35","author":"Molinelli","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2230.2009.03377.x","article-title":"Resorcinol Peels as a Possible Self-Treatment of Painful Nodules in Hidradenitis Suppurativa","volume":"35","author":"Boer","year":"2010","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000228334","article-title":"Combination Therapy with Clindamycin and Rifampicin for Hidradenitis Suppurativa: A Series of 116 Consecutive Patients","volume":"219","author":"Gener","year":"2009","journal-title":"Dermatology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1365-2133.2006.07155.x","article-title":"Clindamycin and Rifampicin Combination Therapy for Hidradenitis Suppurativa","volume":"154","author":"Griffiths","year":"2006","journal-title":"Br. J. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000228337","article-title":"The Effect of Combined Treatment with Oral Clindamycin and Oral Rifampicin in Patients with Hidradenitis Suppurativa","volume":"219","author":"Boer","year":"2009","journal-title":"Dermatology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/ced.12933","article-title":"Oral Clindamycin and Rifampicin Combination Therapy for Hidradenitis Suppurativa: A Prospective Study and 1-Year Follow-Up","volume":"41","author":"Dessinioti","year":"2016","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_32","first-page":"1262","article-title":"Clindamycin Alone May Be Enough. Is It Time to Abandon Rifampicin for Hidradenitis Suppurativa?","volume":"180","author":"Bianchi","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.jaad.2018.11.035","article-title":"Clindamycin versus Clindamycin plus Rifampicin in Hidradenitis Suppurativa Treatment: Clinical and Ultrasound Observations","volume":"80","author":"Cannizzaro","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1111\/bjd.15739","article-title":"Oral Ofloxacin and Clindamycin as an Alternative to the Classic Rifampicin\u2013Clindamycin in Hidradenitis Suppurativa: Retrospective Analysis of 65 Patients","volume":"178","author":"Delaunay","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e13003","DOI":"10.1111\/dth.13003","article-title":"Hidradenitis Suppurativa: Clinical Characteristics and Determinants of Treatment Efficacy","volume":"32","author":"Vural","year":"2019","journal-title":"Dermatol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/ijd.15459","article-title":"Treatment of Hidradenitis Suppurativa with Tetracycline, Doxycycline, or Lymecycline: A Prospective Study","volume":"60","author":"Yao","year":"2021","journal-title":"Int. J. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/ijd.13428","article-title":"Hidradenitis Suppurativa Treated with Tetracycline in Combination with Colchicine: A Prospective Series of 20 Patients","volume":"56","author":"Armyra","year":"2017","journal-title":"Int. J. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Alfei, S., and Zuccari, G. (2022). Recommendations to Synthetize Old and New \u03b2-Lactamases Inhibitors: A Review to Encourage Further Production. Pharmaceuticals, 15.","DOI":"10.3390\/ph15030384"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1586\/14787210.3.1.23","article-title":"Ertapenem: Review of a New Carbapenem","volume":"3","author":"Zhanel","year":"2005","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/jac\/dkv361","article-title":"Efficacy of Ertapenem in Severe Hidradenitis Suppurativa: A Pilot Study in a Cohort of 30 Consecutive Patients","volume":"71","author":"Jais","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"ii75","DOI":"10.1093\/jac\/dkh209","article-title":"Safety and Tolerability of Ertapenem","volume":"53","author":"Teppler","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_42","unstructured":"Patel, P.H., and Hashmi, M.F. (2022). StatPearls, StatPearls Publishing."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jaad.2020.04.092","article-title":"Efficacy of Oral Zinc and Nicotinamide as Maintenance Therapy for Mild\/Moderate Hidradenitis Suppurativa: A Controlled Retrospective Clinical Study","volume":"83","author":"Molinelli","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/jdv.15827","article-title":"Hidradenitis Suppurativa in a Prepubertal Case Series: A Call for Specific Guidelines","volume":"33","author":"Offidani","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e00606-17","DOI":"10.1128\/AAC.00606-17","article-title":"Role of Daptomycin on Burn Wound Healing in an Animal Methicillin-Resistant Staphylococcus Aureus Infection Model","volume":"61","author":"Simonetti","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.5114\/ada.2022.119008","article-title":"Hidradenitis Suppurativa: Bacteriological Study in Surgical Treatment","volume":"39","author":"Gierek","year":"2022","journal-title":"Adv. Dermatol. Allergol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e392","DOI":"10.1111\/jdv.18706","article-title":"Acitretin plus Macrolides and Acitretin Monotherapy in the Management of Hidradenitis Suppurativa","volume":"37","author":"Molinelli","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/jac\/dkx351","article-title":"Metronidazole: An Update on Metabolism, Structure\u2013Cytotoxicity and Resistance Mechanisms","volume":"73","author":"Dingsdag","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000321716","article-title":"Efficacy of Rifampin-Moxifloxacin-Metronidazole Combination Therapy in Hidradenitis Suppurativa","volume":"222","author":"Coignard","year":"2011","journal-title":"Dermatology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jaad.2020.01.007","article-title":"Rifampin-Moxifloxacin-Metronidazole Combination Therapy for Severe Hurley Stage 1 Hidradenitis Suppurativa: Prospective Short-Term Trial and 1-Year Follow-up in 28 Consecutive Patients","volume":"88","author":"Delage","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"(2012). Complete Remission of Severe Hidradenitis Suppurativa Obtained in 4 Patients Using Wide-Spectrum Antimicrobial Treatment. J. Am. Acad. Dermatol., 66, AB46.","DOI":"10.1016\/j.jaad.2011.11.202"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2165\/00003495-200464090-00001","article-title":"Glycopeptide Antibiotics","volume":"64","author":"Courvalin","year":"2004","journal-title":"Drugs"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e02062-19","DOI":"10.1128\/AAC.02062-19","article-title":"New Evidence and Insights on Dalbavancin and Wound Healing in a Mouse Model of Skin Infection","volume":"64","author":"Simonetti","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jdermsci.2008.12.012","article-title":"VEGF, Survivin and NOS Overexpression in Psoriatic Skin: Critical Role of Nitric Oxide Synthases","volume":"54","author":"Simonetti","year":"2009","journal-title":"J. Dermatol. Sci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1517\/17425255.2016.1170807","article-title":"Pharmacokinetics of Linezolid in Critically Ill Patients","volume":"12","author":"Sazdanovic","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.2147\/DDDT.S164515","article-title":"Linezolid: A Review of Its Properties, Function, and Use in Critical Care","volume":"12","author":"Hashemian","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5070\/D3212025709","article-title":"Extensive Hidradenitis Suppurativa (HS) Hurly Stage III Disease Treated with Intravenous (IV) Linezolid and Meropenem with Rapid Remission","volume":"21","author":"Scheinfeld","year":"2015","journal-title":"Dermatol. Online J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/jdv.15332","article-title":"Rates of Antibiotic Resistance\/Sensitivity in Bacterial Cultures of Hidradenitis Suppurativa Patients","volume":"33","author":"Bettoli","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.det.2015.08.013","article-title":"Antibiotic Treatment of Hidradenitis Suppurativa","volume":"34","author":"Bettoli","year":"2016","journal-title":"Dermatol. Clin."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/bjd.17537","article-title":"British Association of Dermatologists Guidelines for the Management of Hidradenitis Suppurativa (Acne Inversa) 2018","volume":"180","author":"Ingram","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/jdv.15233","article-title":"Hidradenitis Suppurativa\/Acne Inversa: A Practical Framework for Treatment Optimization\u2014Systematic Review and Recommendations from the HS ALLIANCE Working Group","volume":"33","author":"Zouboulis","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1590\/abd1806-4841.20198607","article-title":"Consensus on the Treatment of Hidradenitis Suppurativa\u2014Brazilian Society of Dermatology","volume":"94","author":"Duarte","year":"2019","journal-title":"An. Bras. Dermatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000477459","article-title":"Swiss Practice Recommendations for the Management of Hidradenitis Suppurativa\/Acne Inversa","volume":"233","author":"Hunger","year":"2017","journal-title":"Dermatology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11154-016-9328-5","article-title":"Evidence-Based Approach to the Treatment of Hidradenitis Suppurativa\/Acne Inversa, Based on the European Guidelines for Hidradenitis Suppurativa","volume":"17","author":"Gulliver","year":"2016","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/bjd.17265","article-title":"Long-term Clinical Safety of Clindamycin and Rifampicin Combination for the Treatment of Hidradenitis Suppurativa. A Critically Appraised Topic","volume":"180","author":"Albrecht","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/bjd.17615","article-title":"Prolonged Clindamycin and Rifampicin for Hidradenitis Suppurativa: Resist to Prevent Resistance","volume":"180","author":"Hambly","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000431175","article-title":"Hidradenitis Suppurativa\/Acne Inversa: Criteria for Diagnosis, Severity Assessment, Classification and Disease Evaluation","volume":"231","author":"Zouboulis","year":"2015","journal-title":"Dermatology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 Guideline for the Treatment of Hidradenitis Suppurativa\/Acne Inversa","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jaad.2009.08.001","article-title":"Hidradenitis Suppurativa and Smoking","volume":"62","author":"Simonart","year":"2010","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jaad.2016.08.001","article-title":"Patterns of Antimicrobial Resistance in Lesions of Hidradenitis Suppurativa","volume":"76","author":"Fischer","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1111\/bjd.15500","article-title":"Treatment of Hidradenitis Suppurativa with Rifampicin: Have We Forgotten Tuberculosis?","volume":"177","author":"Macedo","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.17423","article-title":"Long-term Clinical Safety of Clindamycin and Rifampicin Combination for the Treatment of Hidradenitis Suppurativa: A Strategy to Reduce Side-effects, Improving Patients\u2019 Compliance","volume":"180","author":"Marasca","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1517\/14740338.2016.1133584","article-title":"Revisiting Doxycycline in Pregnancy and Early Childhood\u2014Time to Rebuild Its Reputation?","volume":"15","author":"Cross","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2340\/00015555-1841","article-title":"Bacteriology of Hidradenitis Suppurativa\u2014Which Antibiotics Are the Treatment of Choice?","volume":"94","author":"Matusiak","year":"2014","journal-title":"Acta Derm. Venereol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s10096-011-1498-1","article-title":"In Vitro Activity and in Vivo Efficacy of Tigecycline Alone and in Combination with Daptomycin and Rifampin against Gram-Positive Cocci Isolated from Surgical Wound Infection","volume":"31","author":"Silvestri","year":"2012","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/ced.14512","article-title":"Long-term Antibiotic Use for the Treatment of Hidradenitis Suppurativa Consistent with Guideline Recommendations","volume":"46","author":"Kitts","year":"2021","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/bjd.15007","article-title":"Bacterial Biofilm in Chronic Lesions of Hidradenitis Suppurativa","volume":"176","author":"Ring","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/jdv.15183","article-title":"Biofilm Production and Antibiotic Susceptibility of Staphylococcus epidermidis Strains from Hidradenitis Suppurativa Lesions","volume":"33","author":"Ardon","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1099\/jmm.0.000649","article-title":"In Vitro and in Vivo Activity of Fosfomycin Alone and in Combination with Rifampin and Tigecycline against Gram-Positive Cocci Isolated from Surgical Wound Infections","volume":"67","author":"Simonetti","year":"2018","journal-title":"J. Med. Microbiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2147\/TCRM.S271445","article-title":"Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization","volume":"17","author":"Simonetti","year":"2021","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/DSS.0000000000000264","article-title":"Recurrence Rate and Patient Satisfaction of CO2 Laser Evaporation of Lesions in Patients with Hidradenitis Suppurativa","volume":"41","author":"Mikkelsen","year":"2015","journal-title":"Dermatol. Surg."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e13282","DOI":"10.1111\/dth.13282","article-title":"Surgical and Postsurgical Wound Care in Hidradenitis Suppurativa","volume":"33","author":"Manfredini","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jaad.2021.10.060","article-title":"Alexandrite Laser as an Adjuvant Therapy in the Management of Mild to Moderate Hidradenitis Suppurativa: A Controlled Prospective Clinical Study","volume":"87","author":"Molinelli","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1524-4725.2011.02186.x","article-title":"Hidradenitis Suppurativa: Surgical and Other Management Techniques","volume":"38","author":"Ellis","year":"2012","journal-title":"Dermatol. Surg."},{"key":"ref_85","unstructured":"(2023, March 30). Recruiting Clinical Trials with Antibiotics in HS, Available online: https:\/\/clinicaltrials.gov\/."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"739","DOI":"10.23736\/S0392-0488.18.06094-7","article-title":"Ixekizumab for Treatment of Moderate to Severe Plaque Psoriasis: Real World Clinical Experience","volume":"155","author":"Diotallevi","year":"2021","journal-title":"G. Ital. Dermatol. Venereol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1080\/17425255.2019.1681969","article-title":"Pharmacodynamics OF TNF \u03b1 Inhibitors for the Treatment of Psoriasis","volume":"15","author":"Campanati","year":"2019","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_88","first-page":"39","article-title":"Biologic Treatments of Psoriasis: An Update for the Clinician","volume":"15","author":"Brownstone","year":"2021","journal-title":"Biologics"},{"key":"ref_89","first-page":"1061","article-title":"Biological Therapies for Atopic Dermatitis: An Update (Review)","volume":"17","author":"Deleanu","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s40265-021-01566-2","article-title":"Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa","volume":"81","author":"Aarts","year":"2021","journal-title":"Drugs"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/bjd.18983","article-title":"Evidence for a \u2018Window of Opportunity\u2019 in Hidradenitis Suppurativa Treated with Adalimumab: A Retrospective, Real-life Multicentre Cohort Study*","volume":"184","author":"Marzano","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1080\/17425255.2020.1810233","article-title":"Metabolic, Pharmacokinetic, and Toxicological Issues of Biologic Therapies Currently Used in the Treatment of Hidradenitis Suppurativa","volume":"16","author":"Molinelli","year":"2020","journal-title":"Expert Opin. Drug Metab. Toxicol."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/6\/978\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:44:18Z","timestamp":1760125458000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/6\/978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,29]]},"references-count":92,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["antibiotics12060978"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics12060978","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,29]]}}}